Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 mai 2015 07h47 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH

RALEIGH, N.C., May 4, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...
23 avr. 2015 12h02 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. Presented at 50th International Liver Conference

RALEIGH, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
24 mars 2015 07h55 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum

RALEIGH, N.C., March 24, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
09 mars 2015 08h07 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)

RALEIGH, N.C., March 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
05 mars 2015 08h07 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD

RALEIGH, N.C., March 5, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
03 mars 2015 09h43 HE | Source: Islet Sciences, Inc.

Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate

RALEIGH, N.C., March 3, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
09 févr. 2015 08h22 HE | Source: Islet Sciences, Inc.

Islet Sciences Engages Investment Bank as Financial Advisor

RALEIGH, N.C., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
06 oct. 2014 08h05 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate

RALEIGH, N.C., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
01 oct. 2014 08h10 HE | Source: Islet Sciences, Inc.

Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.

RALEIGH, N.C., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
06 août 2014 08h00 HE | Source: Islet Sciences, Inc.

Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors

RALEIGH, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...

Page suivante